Home > Newsletters > Drug Industry Daily > FDA to Pay Closer Attention to Extended-Release Generics After Teva’s Generic Wellbutrin Withdrawal
Drug Industry Daily
Nov. 12, 2012 | Vol. 11 No. 222
FDA to Pay Closer Attention to Extended-Release Generics After Teva’s Generic Wellbutrin Withdrawal
The FDA is improving its methods and standards for evaluating some extended-release generics after the withdrawal of Impax and Teva’s 300-mg Wellbutrin XL generic because the product was not therapeutically equivalent to its branded counterpart.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.